Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis

Gerard Ozorio; Bruce McGarity; Haesung Bak; Andrew A. Jordan; Henry Lau; Cathy Marshall

doi:10.5694/j.1326-5377.2007.tb01396.x

Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis

Gerard Ozorio
, Bruce McGarity
, Haesung Bak
, Andrew A. Jordan
, Henry Lau
, Cathy Marshall

Royal Prince Alfred Hospital
Bathurst Base Hospital
Westmead Hospital
Orange Base Hospital

Research output: Contribution to journal › Article › peer-review

68 Citations (Scopus)

Abstract

Autoimmune hepatitis is a rare but increasingly recognised serious complication of treatment with the tumour necrosis factor-α (TNF-α) blocking agent, infliximab. This report adds to the small but growing number of articles describing this significant adverse effect. Baseline liver function should be routinely tested in all patients receiving anti-TNF-α agents, and periodic monitoring for the development of hepatitis is important.

Original language	English
Pages (from-to)	524-526
Number of pages	3
Journal	Medical Journal of Australia
Volume	187
Issue number	9
DOIs	https://doi.org/10.5694/j.1326-5377.2007.tb01396.x
Publication status	Published - 5 Nov 2007
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.5694/j.1326-5377.2007.tb01396.x

Cite this

@article{59eb7e8c54fa4dabaafbf08509cdc515,

title = "Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis",

abstract = "Autoimmune hepatitis is a rare but increasingly recognised serious complication of treatment with the tumour necrosis factor-α (TNF-α) blocking agent, infliximab. This report adds to the small but growing number of articles describing this significant adverse effect. Baseline liver function should be routinely tested in all patients receiving anti-TNF-α agents, and periodic monitoring for the development of hepatitis is important.",

author = "Gerard Ozorio and Bruce McGarity and Haesung Bak and Jordan, \{Andrew A.\} and Henry Lau and Cathy Marshall",

year = "2007",

month = nov,

day = "5",

doi = "10.5694/j.1326-5377.2007.tb01396.x",

language = "English",

volume = "187",

pages = "524--526",

journal = "Medical Journal of Australia",

issn = "0025-729X",

publisher = "Australasian Medical Publishing Company",

number = "9",

}

TY - JOUR

T1 - Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis

AU - Ozorio, Gerard

AU - McGarity, Bruce

AU - Bak, Haesung

AU - Jordan, Andrew A.

AU - Lau, Henry

AU - Marshall, Cathy

PY - 2007/11/5

Y1 - 2007/11/5

N2 - Autoimmune hepatitis is a rare but increasingly recognised serious complication of treatment with the tumour necrosis factor-α (TNF-α) blocking agent, infliximab. This report adds to the small but growing number of articles describing this significant adverse effect. Baseline liver function should be routinely tested in all patients receiving anti-TNF-α agents, and periodic monitoring for the development of hepatitis is important.

AB - Autoimmune hepatitis is a rare but increasingly recognised serious complication of treatment with the tumour necrosis factor-α (TNF-α) blocking agent, infliximab. This report adds to the small but growing number of articles describing this significant adverse effect. Baseline liver function should be routinely tested in all patients receiving anti-TNF-α agents, and periodic monitoring for the development of hepatitis is important.

UR - https://www.scopus.com/pages/publications/38449123106

U2 - 10.5694/j.1326-5377.2007.tb01396.x

DO - 10.5694/j.1326-5377.2007.tb01396.x

M3 - Article

C2 - 17979620

AN - SCOPUS:38449123106

SN - 0025-729X

VL - 187

SP - 524

EP - 526

JO - Medical Journal of Australia

JF - Medical Journal of Australia

IS - 9

ER -

Autoimmune hepatitis following infliximab therapy for ankylosing spondylitis

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this